{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:06:55Z","timestamp":1778897215007,"version":"3.51.4"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.diabet.2017.11.002","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T14:18:01Z","timestamp":1510669081000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-545X","authenticated-orcid":false,"given":"M.","family":"Leggio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Bendini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Caldarone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Severi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"D\u2019Emidio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"Stavri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Armeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2017.11.002_bib0485","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0490","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0495","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0500","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.diabet.2017.11.002_bib0505","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/dc16-S011","article-title":"8: cardiovascular disease and risk management","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0510","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Dav\u00ec","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0515","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.diabet.2017.11.002_bib0520","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.2337\/diacare.26.2007.S87","article-title":"Aspirin therapy in diabetes","volume":"26","author":"American Diabetes Association","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0525","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-5491.2006.01918.x","article-title":"Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care","volume":"23","author":"IDF Clinical Guidelines Task Force","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0530","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"115","author":"Buse","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0535","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0540","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice: Collaborative Group of the Primary Prevention Project","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2017.11.002_bib0545","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0550","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2017.11.002_bib0555","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Cllaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2017.11.002_bib0560","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/diacare.23.8.1119","article-title":"Diabetes duration and cause-specific mortality in the Verona Diabetes Study","volume":"23","author":"Brun","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0565","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2337\/diacare.25.1.43","article-title":"Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study","volume":"25","author":"Roper","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0570","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2017.11.002_bib0575","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1253\/circj.CJ-66-0053","article-title":"Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011)","volume":"77","author":"JCS Joint Working Group","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0580","doi-asserted-by":"crossref","first-page":"b4531","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2017.11.002_bib0585","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/dc09-1297","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes","volume":"32","author":"Calvin","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0590","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrendo.2010.169","article-title":"Aspirin for primary prevention of cardiovascular disease in diabetes mellitus","volume":"6","author":"Pignone","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0595","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/CIR.0b013e3181e3b133","volume":"121","author":"Pignone","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0600","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0605","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jacc.2010.04.003","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes","volume":"55","author":"Pignone","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0610","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0615","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0620","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1172\/JCI200421446","article-title":"Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice","volume":"114","author":"Kobayashi","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2017.11.002_bib0625","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM200009213431202","article-title":"Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding","volume":"343","author":"Lanas","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0630","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0635","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1586\/14779072.2014.964687","article-title":"Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes","volume":"12","author":"Gargiulo","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.diabet.2017.11.002_bib0640","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0645","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jama.2015.0809","article-title":"Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction","volume":"313","author":"Schjerning Olsen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2017.11.002_bib0650","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0655","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0660","doi-asserted-by":"crossref","first-page":"27A","DOI":"10.1016\/j.amjcard.2008.11.020","article-title":"Variability in responsiveness to oral antiplatelet therapy","volume":"103","author":"Angiolillo","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0665","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1538-7836.2005.01351.x","article-title":"Aspirin resistance: position paper of the Working Group on aspirin resistance","volume":"3","author":"Michelson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.diabet.2017.11.002_bib0670","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","article-title":"Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation","volume":"46","author":"Tantry","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0675","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2003.08.033","article-title":"Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus","volume":"92","author":"Keating","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0680","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s001250051598","article-title":"Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro","volume":"44","author":"Assert","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2017.11.002_bib0685","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/09537100600760814","article-title":"Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects","volume":"17","author":"Vaidyula","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.diabet.2017.11.002_bib0690","doi-asserted-by":"crossref","first-page":"23696","DOI":"10.1074\/jbc.272.38.23696","article-title":"Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart","volume":"272","author":"Algenstaedt","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2017.11.002_bib0695","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1074\/jbc.M305474200","article-title":"IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi","volume":"279","author":"Ferreira","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2017.11.002_bib0700","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.ATV.15.8.1114","article-title":"Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria","volume":"15","author":"Kario","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.diabet.2017.11.002_bib0705","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2362.1994.tb02424.x","article-title":"Platelet turnover in advanced diabetes","volume":"24","author":"Winocour","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2017.11.002_bib0710","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.diabet.2017.11.002_bib0715","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12185-010-0652-3","article-title":"Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes","volume":"92","author":"Addad","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0720","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.diabet.2017.11.002_bib0725","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1161\/CIRCULATIONAHA.106.675587","article-title":"Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study","volume":"115","author":"Gurbel","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0730","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.2337\/db07-0707","article-title":"The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study","volume":"56","author":"DiChiara","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2017.11.002_bib0735","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0740","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0745","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.diabet.2017.11.002_bib0750","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus","volume":"268","author":"ETDRS Investigators","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2017.11.002_bib0755","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-123-9-199511010-00002","article-title":"Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing: The Asymptomatic Cervical Bruit Study Group","volume":"123","author":"C\u00f4t\u00e9","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0760","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0765","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","article-title":"Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial","volume":"261","author":"Catalano","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0770","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.diabet.2017.11.002_bib0775","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.diabet.2017.11.002_bib0780","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2017.11.002_bib0785","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2017.11.002_bib0790","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2017.11.002_bib0795","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2017.11.002_bib0800","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2017.11.002_bib0805","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2017.11.002_bib0810","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","article-title":"Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin","volume":"107","author":"Bartolucci","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0815","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in the primary prevention of cardiovascular disease","volume":"124","author":"Raju","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0820","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ahj.2011.04.006","article-title":"Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials","volume":"162","author":"Berger","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0825","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0830","doi-asserted-by":"crossref","first-page":"e90286","DOI":"10.1371\/journal.pone.0090286","article-title":"Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2017.11.002_bib0835","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.amjmed.2015.10.046","article-title":"Updated meta-analysis of aspirin in primary prevention of cardiovascular disease","volume":"129","author":"Raju","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0840","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M15-2113","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force","volume":"164","author":"Guirguis-Blake","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0845","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0850","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.diabet.2017.11.002_bib0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17430","article-title":"Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews","volume":"17","author":"Sutcliffe","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.diabet.2017.11.002_bib0860","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1253\/circj.CJ-13-0307","article-title":"Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk","volume":"77","author":"Okada","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0865","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0870","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0875","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0880","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial","volume":"135","author":"Saito","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0885","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.diabres.2009.09.029","article-title":"Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis","volume":"87","author":"Zhang","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2017.11.002_bib0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181f1fba8","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis","volume":"341","author":"Stavrakis","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.diabet.2017.11.002_bib0895","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2840-10-25","article-title":"Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"10","author":"Butalia","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0900","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dme.13133","article-title":"Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials","volume":"34","author":"Kunutsor","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0905","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryden","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2017.11.002_bib0910","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0915","first-page":"60","article-title":"Standards of medical care in diabetes\u20132016","volume":"39","author":"Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0920","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2337\/dc16-S011","article-title":"Cardiovascular disease and risk management","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.11.002_bib0925","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0930","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2017.11.002_bib0935","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The multifaceted clinical readouts of platelet inhibition by low-dose aspirin","volume":"66","author":"Patrono","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2017.11.002_bib0940","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","article-title":"Aspirin for the prevention of cancer incidence and mortality: sstematic evidence reviews for the U.S. Preventive Services Task Force","volume":"164","author":"Chubak","year":"2016","journal-title":"Ann Intern Med"},{"issue":"25\u00a0Suppl.\u00a02","key":"10.1016\/j.diabet.2017.11.002_bib0945","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0950","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","article-title":"Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus","volume":"134","author":"Capodanno","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2017.11.002_bib0955","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/db15-0936","article-title":"In vivo platelet activation and aspirin responsiveness in type 1 diabetes","volume":"65","author":"Zaccardi","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2017.11.002_bib0960","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236361730575X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236361730575X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T07:23:38Z","timestamp":1659857018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236361730575X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S126236361730575X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2017.11.002","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}